# Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)

> **NCT02577029** · PHASE2 · TERMINATED · sponsor: **Arrowhead Pharmaceuticals** · enrollment: 79 (actual)

## Conditions studied

- Hepatitis B
- Hepatitis D

## Interventions

- **DRUG:** ARC-520
- **DRUG:** entecavir
- **BIOLOGICAL:** pegylated interferon alpha 2a
- **DRUG:** tenofovir disoproxil
- **DRUG:** antihistamine

## Key facts

- **NCT ID:** NCT02577029
- **Lead sponsor:** Arrowhead Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-12
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 79 (ACTUAL)
- **Why stopped:** Company decision to discontinue trial
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02577029

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02577029, "Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02577029. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*